LLOYD

Ladder Of Success

NEWS UPDATE

Date: 09/03/2026

Cipla USA Recalls Nilotinib Anti-Cancer Capsules Over Manufacturing Issue: USFDA



Cipla USA, the American subsidiary of Indian pharmaceutical giant Cipla, has initiated a voluntary Class III recall of over 400 cartons of its generic anti-cancer drug Nilotinib Capsules in the United States, as reported by the US Food and Drug Administration (USFDA). The affected products include Nilotinib in 150 mg and 200 mg strengths, with specific batches totaling 271 cartons of one lot and 164 cartons of another (exact lot numbers not fully detailed in reports). The recall, started on February 18, 2026, stems from a manufacturing issue involving failed tablet/capsule specifications (such as out-of-specification results for capsule description). Classified as Class III, the USFDA states that use of or exposure to the violative product is not likely to cause adverse health consequences. This precautionary measure underscores Cipla's commitment to quality and patient safety in the US market, where the drug is distributed as a generic version for treating certain cancers like chronic myeloid leukemia.

Source:
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-usa-recalls-nilotinib-anti-cancer-capsules-over-manufacturing-issue-usfda/articleshow/129287780.cms